Pfizer Says Lyrica Fails in Diabetes Trial, Halts HIV Study
This article is for subscribers only.
Pfizer Inc.’s Lyrica, approved for use in fibromyalgia, didn’t work to control painful nerve damage from diabetes in one study, and the company halted a second trial in nerve-damaged HIV patients.
Lyrica, with sales of $3.7 billion last year, didn’t significantly lessen the pain of diabetes patients with nerve damage who were switched to the drug after another treatment failed, New York-based Pfizer said. The company also halted a trial for HIV patients, after an interim analysis showed no difference between Lyrica and a placebo.